retatrutide vs orforglipron trial results news today Lilly's triple agonist achieves 16.8% weight loss in phase 3 Lilly oral GLP-1 phase – Orforglipron vs Retatrutide | Ageless

Wing RR, Lang W, Wadden TA, et al

The impact on hunger and portion sizes varies from person to person, and while some people notice these changes quickly, others may take longer to experience a significant reduction in appetite

RELATED: Worried about 'Ozempic butt?' New drug could stop muscle loss tied to weight loss injections Obesity declines, diabetes levels stabilize Dig deeper: After peaking at 39.9% in 2022, the national adult obesity rate has fallen to 36.4% in 2026, mirroring ring GLP-1 usage

Ipamorelin is added to support a stronger GH pulse

But honestly

Visceral versus subcutaneous fat While the trial did not break down visceral and subcutaneous fat reduction separately using imaging for all participants, the liver fat data serves as a strong proxy